Beta-thalassemia overview

Jump to navigation Jump to search

Beta-thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Beta-thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Beta-thalassemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Beta-thalassemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Beta-thalassemia overview

CDC on Beta-thalassemia overview

Beta-thalassemia overview in the news

Blogs on Beta-thalassemia overview

Directions to Hospitals Treating Beta-thalassemia

Risk calculators and risk factors for Beta-thalassemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

Historical Perspective

The Thalassemia term was invented by a hematologist, Dr. Thomas Cooley, in 1925. It has a Greek origin and consists of Thalassa and Emia which mean sea and blood, respectively. The diagnostic certainty was ultimately established with hemoglobin electrophoresis in the 20th century.

Classification

Beta-Thalassemia is classified based on the severity and the type of responsible mutation. It mainly has 3 types: β thalassemia minor, β thalassemia major, Thalassemia intermedia. There are less common types such as E/Beta-thalassemia, autosomal dominant Beta-thalassemia and atypical Beta-Thalassemia.

Pathophysiology

Beta-Thalassemia is an inherited disorder in hemoglobulin production due to a variety of genetic mutations in the gene responsible for Beta-globin production (HBB gene, on chromosome 11). The effects of beta-thalassemia on red blood cell morphology and function are significantly detrimental. Beta-Thalassemia contributes to abnormal hemoglobin and red blood cells (RBCs) that have impaired function in efficient oxygen delivery to different body tissues, which is called the state of anemia. As mutated genes are passed down, the shortage of functional red blood cells begins affecting the body from early infancy, and the lifelong persistence of insufficiency in beta-globin production results in chronic anemia. Hepatosplenomegaly, delayed developmental milestones, jaundice, bone problems, and different infections might happen in early infancy.

Differentiating Beta-thalassemia from other Diseases

Beta-thalassemia may have similar features of other conditions such as iron deficiency anemia, sideroblastic anemia, Alpha-thalassemia, other hemolytic anemia and other hemoglobinopathies including sickle cell anemia. To differentiate these conditions, history and physical examination, electrophoresis of hemoglobin, DNA analysis and iron level assessments would be useful.

Epidemiology and Demographics

The prevalence of beta-thalassemia carrier is 1.5% of the world population which is mainly in regions with a historical association with malaria, including the Mediterranean, Middle East, Central Asia, Indian subcontinent, and parts of Southeast Asia and Africa. The incidence of beta-thalassemia is 42,000 per year. It affects both males and females in a similar demographic manner.

Risk Factors

In general, positive family history and specific ethnicities are the major risk factors for beta-thalassemia. On the other hand, lack of awareness and education about the screening for beta-thalassemia, limited resources for screening programs and consanguineous marriages are contributing factors for increasing the risk of beta-thalassemia.

Natural History, Complications and Prognosis

Without regular blood transfusions, affected individuals by major beta-thalassemia typically develop severe anemia and other complications such as pulmonary hypertension, right heart failure, iron overload, infections early in life, while beta-thalassemia intermedia patients would have a variable clinical course, complications, and prognosis. Beta-thalassemia minor subjects would not have significant symptoms, while in some cases might have an increased risk for iron deficiency anemia. Iron overload complications happen in transfusion-dependent thalassemia. The prognosis of beta-thalassemia depends on the severity of the disease and the presence of complications such as iron overload-related complications and cardiovascular disorders.

Diagnosis

History and Symptoms

Patients with beta-thalassemia major may manifest with severe anemia, failure to thrive, pallor, jaundice, abdominal enlargement, fatigue, recurrent fever attacks, growth retardation and poor muscle tone early in childhood. Multiple transfusions can cause arthritis, abdominal pain, bronzed or grayish skin, loss of libido, hormonal imbalances, and cognitive problems. Intermedia variant patients might experience moderate anemia, splenomegaly, bone changes, and intermittent need for blood transfusions at different ages. Patients with beta-thalassemia minor are basically asymptomatic or have minor anemic symptoms.

Physical Examination

In physical examination of patients with beta-thalassemia major, pallor, jaundice, hepatosplenomegaly, frontal bossing, long bone abnormalities, skull expansion with frontal, malar, and nasal bridge prominences, maxillary hypertrophy, malocclusion of jaw, short trunk, genu valgum, delayed sexual development, low blood pressure and irregular pulse may be noticeable. Beta-thalassemia minor does not have significant signs and manifestations.

Laboratory Findings

The initial work-up for diagnosis of beta-thalassemia includes complete blood count and hemoglobin electrophoresis which may indicate low hemoglobin level, MCV, MCH and high hemoglobin F and A2. For advanced assessment, there are other methods such as: high-performance liquid chromatography (HPLC), capillary zone electrophoresis (CE) systems, chorionic villus sample, amniotic fluid evaluation, DNA analysis, PCR and genome sequencing.

X Ray

In X-ray evaluation, thinning of bones and expanded bone marrow spaces can be observed.

CT

CT scan is not a routine work-up in beta-thalassemia. However, the abdominal CT scan may reveal Hepatosplenomegaly due to Extramedullary hematopoiesis.

MRI

Abdominopelvic MRI can suggest hepatosplenomegaly. MRI with T2 star sequence is a particular sequence of MRI that specifically assesses for iron overload states. MRI with T2 star of the heart or liver can help determine the degree of iron overload.

Ultrasound

Ultrasound is not a routine work-up in beta-thalassemia. However, the abdominal ultrasound may reveal Hepatosplenomegaly due to Extramedullary hematopoiesis.

Other Imaging Findings

There are no other imaging findings for beta-thalassemia.

Other Diagnostic Studies

Serum ferritin levels, liver function tests, and genetic testing to identify specific beta-thalassemia mutations are other diagnostic studies which may help to confirm the diagnosis.

Treatment

Medical Therapy

The mainstay of treatment for beta-thalassemia major is blood transfusion. Chelation therapy is also required to manage iron overload resulting from repeated transfusions. In less severe cases, folic acid supplementation may be recommended to support red blood cell production. Bone marrow transplantation is the only cure for thalassemia, and is indicated for patients with severe thalassemia major. Untreated thalassemia major eventually leads to death, usually by heart failure; therefore, birth screening is very important.

In beta-thalassemia minor, a serum ferritin test can determine what their iron levels are and guide them to further treatment if necessary.

Surgery

Surgical intervention is frequently required to guarantee optimum management of the accompanying morbidity in beta-thalassemia cases. The most prevalent types of surgical interventions associated with beta-thalassemia include splenectomy, cholecystectomy, leg ulcers, fractures, and extramedullary pseudotumor.

Primary Prevention

Primary prevention strategies are carrier screening, genetic counseling, and prenatal testing to identify at-risk couples and provide appropriate guidance regarding family planning options.

Secondary Prevention

Secondary prevention measures would be needed after the initiation of blood transfusions with regular monitoring of iron overload, maintaining appropriate transfusion and chelation therapy regimens, and managing potential complications such as infections or organ dysfunction.

Cost-Effectiveness of Therapy

The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as access to healthcare resources, availability of blood products, affordability of chelation therapy, and overall disease management.

Future or Investigational Therapies

Promising future therapies for beta-thalassemia major include gene therapy, stem cell transplantation, and novel approaches targeting gene editing or gene regulation to enhance the production of functional beta-globin chains.



Template:WikiDoc Sources



Template:WikiDoc Sources